The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Cognitive behavior therapy (CBT), as exemplified by the model of psychotherapy developed and refined over the past 40 years by A.T. Beck and colleagues, is one of the treatments of first choice for ambulatory depressive and anxiety disorders. Over the past several decades, there have been vigorous efforts to adapt CBT for treatment of more severe mental disorders, including schizophrenia and the more chronic and/or treatment refractory mood disorders. These efforts have primarily studied CBT as an adjunctive therapy, i.e., in combination with pharmacotherapy. Given the several limitations of state-of-the-art pharmacotherapies for these severe mental disorders, demonstration of clinically meaningful additive effects for CBT would have important implications for improving public health. This paper reviews the key developments in this important area of therapeutics, providing a summary of the current state of the art and suggesting directions for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring the global burden of disease
Murray, C. J. L., & Lopez, A. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1201534 · Cited by 1,818 · cited 1×
“Worldwide, millions of people who are treated for those conditions do not obtain adequate responses to pharmacotherapy and, collectively, major depressive disorder, bipolar disorder and schizophrenia constitute the world’s greatest public health problem (1), costing billions of dollars of lost human capital.”
BackgroundHoffman, S. G., & Smits, J. A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0415 · Cited by 1,420
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 3×
“The results at the end of the 12 week acute phase strongly favored the combination strategy, within an advantage in intent-to-treat response and remission rates of approximately 20% (36).”
BackgroundInfluentialSelf-citationWykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029 · cited 2×
“In one of the most influential metaanalyses, Wykes et al (6) found an average effect size for target symptom (33 studies) of 0.”
BackgroundInfluentialNemeroff, C. B., Heim, C. M., Thase, M. E., Klein, D. N., Rush, A. J., Schatzberg, A. F., Ninan, P. T., McCullough, J. P., Weiss, P. M., Dunner, D. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336126100 · Cited by 829
Self-citationScott, J., Paykel, E., Morriss, R., Bentall, R., Kinderman, P., Johnson, T., Abbott, R., & Hayhurst, H. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.313 · Cited by 566
Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder
McGrath, C. L., Kelley, M. E., Holtzheimer, P. E., Dunlop, B. W., Craighead, W. E., Franco, A. R., Craddock, R. C., & Mayberg, H. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.143 · Cited by 561 · cited 1×
“In the future, it may be possible to further refine the selection of patients who are likely to benefit from adjunctive CBT by use of neuroimaging techniques to gauge the activity of relevant circuits, as suggested by some recent findings (48-51).”
ResultMiklowitz, D. J., Otto, M. W., Frank, E., Reilly-Harrington, N. A., Wisniewski, S. R., Kogan, J. N., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Gyulai, L., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.419 · Cited by 537
Self-citationJauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.116285 · Cited by 517
Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
Thase, M. E. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230043006 · Cited by 515 · cited 2×
“However, in a meta-analysis of individual patient data from studies of major depressive disorder that utilized either CBT or interpersonal psychotherapy (IPT), either singly or in combination with antidepressants, Thase et al (32) found a modest overall advantage for combined therapy, which was moderated by a signific…”
BackgroundSelf-citation
Cited by
Zhang, Q., Yang, X., Song, H., & Jin, Y. (2020) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2020.101111 · Cited by 60
Ehrt-Schäfer, Y., Rusmir, M., Vetter, J., Seifritz, E., Müller, M., & Kleim, B. (2023) · JMIR Mental Health · doi:10.2196/43882 · Cited by 24
“Nevertheless, there is limited research on the feasibility and effects of bPT for patients with severe mental illnesses (SMIs) [12,13,22,23], even though there is mounting evidence regarding the effectiveness of psychotherapy for this population [24-28].”
BackgroundWaller, H., Landau, S., Fornells-Ambrojo, M., Jolley, S., McCrone, P., Halkoree, R., Basit, N., Iredale, C., Tunnard, C., Zala, D., et al. (2018) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2017.12.004 · Cited by 21
Martins, M. J. R. V., Castilho, P., Carvalho, C. B., Pereira, A. T., Santos, V., Gumley, A., & de Macedo, A. F. (2017) · European Psychologist · doi:10.1027/1016-9040/a000283 · Cited by 11
Adjuvant Psychotherapies to Prevent Relapse in Bipolar Disorder: A Randomized Clinical Trial
Hautzinger, M., & A2 BipoLife Consortium (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.1310 · Cited by 10
Metadata
- Authors
- Thase, M. E., Kingdon, D., & Turkington, D.
- Venue
- World Psychiatry
- Publisher
- Wiley
- Published
- 2014-10
- Volume
- 13
- Issue
- 3
- Pages
- 244-250
- ISSN
- 1723-8617 (ISSN-L)
- OpenAlex
- W2053952802
- Cited by
- 58
- References
- 26
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.